Malignant Melanoma- Integrative Therapies Enhance Outcomes

Share Button

Integrative Therapy for Malignant Melanoma- Enhance the Efficacy of Conventional Chemotherapy While Reducing Toxicity

As you can see from the illustration below, skin cancer is all its forms is pretty complicated. The outlook for malignant melanoma is not hopeful, at least seen through conventional oncology’s eyes.

According to research “The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although surgery and radiation therapy have a role in the treatment of metastatic disease, systemic therapy is the mainstay of treatment for most patients. Single-agent chemotherapy ( Dacarbazine) is well tolerated but is associated with response rates of only 5% to 20%. Combination chemotherapy and biochemotherapy may improve objective response rates but do not extend survival and are associated with greater toxicity. Immunotherapeutic approaches such as high-dose interleukin-2 are associated with durable responses in a small percentage of patients.

Click the image below to enlarge the image-

Skin Cancer Mind Map

I have lived with an incurable blood cancer called multiple myeloma for more than 2o years. I am pointing this out because conventional therapies did little for me. I have lived in complete remission from my cancer by living an evidence-based, non-toxic, non-conventional, anti-myeloma lifestyle through nutrition, supplementation, bone health and lifestyle therapies.

I think patients with malignant melanoma should consider thinking outside the conventional oncology box. Curcumin is a good example of a well-researched anti-oxidant that integrates with dacarbazine to enhance it’s efficacy against malignant melanoma.

To learn more about integrative, complimentary and other forms of evidence-based, non-conventional melanoma therapies, scroll down the page, post a question or comment and I will reply to you ASAP.

Thank you,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.

“Malignant melanoma is a highly aggressive form of skin cancer with a high mortality rate if not discovered in early stages. Although a limited number of treatment options for melanoma currently exist, patients with a more aggressive form of this cancer frequently decline treatment…

Beneficial effects such as melanoma tumor burden reduction with pyknotic nuclei, decreased nuclei/cytoplasmic ratio and nuclear degradation occurred after DM-1 treatment…”

Leave a Comment: